Clinical trials: Bone Marrow Fibrosis, active
Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF)
Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis
In this open-label single arm phase 2 study, approximately 20 patients with MF demonstrating suboptimal response to ruxolitinib monotherapy will be enrolled.
- Conditions
- Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
- Trial name
- NCT06770842
- Testing
- Ropeginterferon alfa-2b (BESREMi®)
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Myelofibrosis
A Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQ05105 Tablets in Subjects With Intermediate/High-risk Myelofibrosis
This is an open-label, single-arm, multi-center phase II study consisting of two cohorts. Cohort 1 evaluates the pharmacokinetics (PK) of TQ05105 in myelofibrosis participants with normal, mild, or moderate renal impairment to…
- Trial name
- NCT07551427
- Testing
- TQ05105 Tablets (Rovadicitinib Tablets)
- Where
- 24 sites in China
- Volunteers
- 51 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Myelofibrosis
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to…
- Trial name
- NCT04576156
- Testing
- Imetelstat, Best Available Therapy (BAT)
- Where
- 144 sites in United States, Argentina and 24 more
- Volunteers
- 327 people
- Sponsor
- Geron Corporation
Primary Myelofibrosis, Secondary Myelofibrosis
Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis
This phase II trial studies how well administering ruxolitinib before, during, and after allogeneic hematopoietic stem cell transplantation works in preventing graft versus host disease and improving transplant outcomes in…
- Trial name
- NCT04384692
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Alcoholic Liver Cirrhosis
Long-Term Follow-up of Patients With Alcoholic Liver Cirrhosis Treated With Cellgram-LC
The goal of this observational study is to learn about the long-term safety of Cellgram-LC in patients with alcoholic liver cirrhosis who previously received Cellgram-LC in the PMC-P-07 study.
- Trial name
- NCT05093881
- Where
- 14 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Pharmicell Co., Ltd.
Primary Myelofibrosis
A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory…
- Trial name
- NCT04446650
- Testing
- Fedratinib
- Where
- 21 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Bristol-Myers Squibb
Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
- Conditions
- Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
- Trial name
- NCT07340138
- Testing
- Pelabresib, Ruxolitinib
- Where
- 3 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Novartis Pharmaceuticals
MF
A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
This trial adopts a single arm, open label, multi center clinical trial design, with a planned enrollment of approximately 64 participants in the intermediate to high risk MF trial who are refractory, relapsed, or intolerant to…
- Trial name
- NCT07443306
- Testing
- Flonoltinib Maleate
- Where
- 2 sites in China
- Volunteers
- 64 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
GVHD, Hematopoietic Cell Transplantation (HCT)
TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT
The purpose of this study is to test the feasibility and safety of early cessation of tacrolimus following allogeneic hematopoietic cell transplantation (HCT).
- Conditions
- GVHD, Hematopoietic Cell Transplantation (HCT), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes
- Trial name
- NCT07302776
- Testing
- Tacrolimus, Early Tacrolimus Taper Strategy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Myelofibrosis, Myelodysplastic Syndrome
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy or combination with ruxolitinib for participants with myelofibrosis (MF) and other myeloid neoplasms.
- Conditions
- Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
- Trial name
- LIMBER (NCT04279847)
- Testing
- INCB057643, Ruxolitinib
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 140 people
- Sponsor
- Incyte Corporation
MF
A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
This trial adopts a multicenter, open label, positive drug parallel controlled clinical trial design, with a planned enrollment of approximately 105 participants in the MF trial.
- Trial name
- NCT07317700
- Testing
- Flonoltinib 75mg, Ruxolitinib Phosphate
- Where
- 2 sites in China
- Volunteers
- 105 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Chronic Myeloproliferative Disorders, Cognitive/Functional Effects
Registry of Older Patients With Cancer
RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.
- Conditions
- Chronic Myeloproliferative Disorders, Cognitive/Functional Effects, Leukemia, Lymphoma
- Trial name
- NCT01137825
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
MF,PMF,PPV-MF,PET-MF
A Phase II Clinical Trial of Flonoltinib Maleate Tablet in Intermediate-High Risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants.
- Trial name
- NCT06457425
- Testing
- Flonoltinib 50mg, Flonoltinib 100mg, Ruxolitinib
- Where
- 2 sites in China
- Volunteers
- 75 people
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Myelofibrosis
Bomedemstat (IMG-7289) in Combination With Momelotinib in Patients With Myelofibrosis
This is an open-label, single-arm, Phase 2 interventional study designed to evaluate the safety and efficacy of Bomedemstat (IMG-7289) when added to Momelotinib in patients with Myelofibrosis (MF) who exhibit a suboptimal…
- Trial name
- NCT07424950
- Testing
- bomedemstat
- Volunteers
- 40 people
- Sponsor
- United Lincolnshire Hospitals NHS Trust
Chronic Myeloproliferative Neoplasms
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
This is a multicenter, open label, long-term study testing the long-term safety, tolerability and efficacy of givinostat in patients with Polycythemia Vera, Essential Thrombocythemia, primary Myelofibrosis, Post-Polycythemia Vera…
- Trial name
- NCT01761968
- Testing
- givinostat
- Where
- 15 sites in Germany, Italy and 1 more
- Volunteers
- 90 people
- Sponsor
- Italfarmaco
Bone Marrow Fibrosis
Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability
The present study will be a multicenter, prospective phase II-study comparing efficacy of allogeneic SCT for patients with myelofibrosis who have a suitable stem cell donor after a 3 months Ruxolitinib induction therapy with…
- Trial name
- NCT03333187
- Testing
- Allogeneic stem cell transplantation, Ruxolitinib continuous therapy
- Where
- 14 sites in Germany
- Volunteers
- 87 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Secondary AML, Myelofibrosis
A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis
The purpose of this study is to test the safest and most effective dose of a new investigational drug, rebecsinib. Participants in this study will have either Secondary Acute Myeloid Leukemia (sAML) that has either returned…
- Trial name
- NCT07250646
- Testing
- rebecsinib
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Aspera Biomedicines, Inc.
Myelofibrosis, High-Risk Cancer
Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
The purpose of this research study is to see how effective hematopoietic stem cell transplantation (HCT) is compared to best available non-transplant therapies (BAT) in patients with high risk myelofibrosis.
- Conditions
- Myelofibrosis, High-Risk Cancer, Bone Marrow Cancer
- Trial name
- ALLO-BAT (NCT04217356)
- Testing
- Hematopoietic stem cell transplant, Ruxolitinib, Hydroxyurea
- Where
- 5 sites in Canada
- Volunteers
- 90 people
- Sponsor
- University Health Network, Toronto
Myelofibrosis
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls.
- Trial name
- NCT02934477
- Testing
- Hematopoietic Stem Cell Transplant
- Where
- United States
- Volunteers
- 650 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Myelofibrosis
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
The researchers are doing this study to find out whether the combination of ruxolitinib and ulixertinib is a safe and effective treatment for people with myelofibrosis.
- Trial name
- NCT06773195
- Testing
- Ulixertinib, Ruxolitinib
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Memorial Sloan Kettering Cancer Center